Dr. Nicole C. Schmitt, MD, FACS
Claim this profileWinship Cancer Institute at Emory University
Area of expertise
Cancer
Nicole C. Schmitt, MD, FACS has run 4 trials for Cancer. Some of their research focus areas include:
Squamous Cell Carcinoma
Nicole C. Schmitt, MD, FACS has run 4 trials for Squamous Cell Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
Winship Cancer Institute At Emory University
Winship Cancer Institute / Emory University School Of Medicine
Clinical Trials Nicole C. Schmitt, MD, FACS is currently running
Remote Audiometry
for Hearing Loss in Head and Neck Cancers
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation. Cisplatin, a chemotherapy often used to treat head and neck cancers, and radiation given near the ear can cause hearing loss in some patients. Hearing loss can have a major negative impact on quality of life, contributing to social isolation and frustration. Identifying hearing changes may allow treatment changes to prevent further loss. Audiometry measures hearing loss using a graphic record of the softest sounds that a person can hear at various frequencies. It is recommended patients have a hearing test before, during and after treatment to monitor for any hearing loss. This is usually done in the office and performed on the same day as other visits whenever possible, however, patients who live far away or have stage IV cancer, may have more difficulty coming back for hearing tests. Offering close to home and remote audiometry may improve monitoring for hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation.
Recruiting
1 award
N/A
3 criteria
Atorvastatin
for Hearing Loss in Head and Neck Cancer
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and radiation Design: Participants will be screened with their medical records. Participants currently taking a cholesterol-lowering statin medication are invited to participate in the observational arm of the study. Those not taking such a medication are invited to participate in the interventional arm of the study. All participants will have 3 study visits for the purpose of evaluating hearing. One before starting cisplatin treatment, one within 3 months of completing cancer treatment, and one within 2 years of completing cancer treatment. They will have tympanograms. A small flexible tip will be placed in the ear canal. A puff of air will be delivered to assess mobility of the ear drum. They will have hearing tests. They will wear headphones. They will listen to tones that vary in loudness. They will be asked to indicate when they hear a sound. They will complete 3 questionnaires at the time of each hearing test. Participants will have 2 visits for blood tests. These will occur upon consent and 12 weeks after. They will be randomly assigned to take the study drug or placebo orally, once daily. They will take it during cisplatin treatment and for 3 months after treatment. Long-term follow up will include a chart review 2 years after participants complete their cisplatin therapy.
Recruiting
0 awards
Phase 2
8 criteria
More about Nicole C. Schmitt, MD, FACS
Clinical Trial Related
5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Nicole C. Schmitt, MD, FACS has experience with
- Pembrolizumab
- Lovastatin
- Audiometric Test
- Cisplatin
- Atorvastatin
- Placebo
Breakdown of trials Nicole C. Schmitt, MD, FACS has run
Cancer
Squamous Cell Carcinoma
Sinus Cancer
Head and Neck Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicole C. Schmitt, MD, FACS specialize in?
Nicole C. Schmitt, MD, FACS focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Nicole C. Schmitt, MD, FACS currently recruiting for clinical trials?
Yes, Nicole C. Schmitt, MD, FACS is currently recruiting for 3 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Nicole C. Schmitt, MD, FACS has studied deeply?
Yes, Nicole C. Schmitt, MD, FACS has studied treatments such as Pembrolizumab, Lovastatin, Audiometric Test.
What is the best way to schedule an appointment with Nicole C. Schmitt, MD, FACS?
Apply for one of the trials that Nicole C. Schmitt, MD, FACS is conducting.
What is the office address of Nicole C. Schmitt, MD, FACS?
The office of Nicole C. Schmitt, MD, FACS is located at: Winship Cancer Institute at Emory University, Atlanta, Georgia 30322 United States. This is the address for their practice at the Winship Cancer Institute at Emory University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.